Urinary tract infection in adults by Coetzer, E
Infection of the urinary tract (UTI) is frequently encountered in clinical practice —
in the USA these infections account for approximately 7 million office visits annu-
ally. The reported incidence in women is 11% per year and approximately 50%
of all women have at least one UTI in their lifetime.1,2 UTI accounts for 40% of
nosocomial infections and catheter use is the leading cause.3 Up to 25% of hos-
pitalised patients undergo catheterisation and the incidence of bacteriuria is 5%
per day.4
Symptomatic UTI exists when clinical symptoms are attributable to bacteria in the
normally sterile urinary tract. Symptoms vary depending on the site of infection
(lower or upper tract). 
• Uncomplicated UTI describes infection where the urinary tract is entirely nor-
mal. 
• Complicated UTI occurs where the urinary tract is compromised, either struc-
turally, functionally, metabolically or immunologically.
Asymptomatic UTI is identified when organisms can be isolated in appropriate
numbers from urine in the absence of symptoms.
Adult patients with UTI can be categorised according to different clinical syn-
dromes (Fig. 1).
DEFINITIONS AND DIAGNOSTIC TESTS1,5
Bacterial invasion of the urinary tract causes an inflammatory response resulting
in bacteriuria and pyuria. Indirect dipstick tests and/or direct microscopy of
urine should be performed in all patients suspected of having a UTI.
Indirect dipstick tests
Dipstick nitrite is used as a surrogate marker for bacteriuria. Infection due to
uropathogens which do not reduce nitrate to nitrite (e.g. Gram-positive cocci)
may be responsible for false-negative results. 
The dipstick leukocyte esterase test is a rapid, convenient and cheap screening
tool for detecting pyuria. 
However, neither is diagnostic of significant bacteriuria, and urine microscopy
and culture are required for confirmation.
Microscopic urinalysis and culture
Pyuria is the presence of white blood cells (WBC) in the urine and is indicative
of urothelial inflammation.  This is a nonspecific finding, but the vast majority of
symptomatic patients have pyuria. In a random clean-catch urine specimen ≥10
WBC/mm3 will be consistent with infection. WBC casts in the presence of symp-
toms is strong evidence for pyelonephritis. Sterile pyuria warrants investigations
for other conditions such as tuberculosis, calculi or urinary tract malignancy.
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URINARY TRACT INFECTION IN
ADULTS
Urinary tract infection in adults is common and may be complicated or uncomplicated.
Bacteriuria is the presence of bacteria
in normally sterile urine. It implies that
micro-organisms are from the urinary
tract and not contaminants from the
distal urethra, vagina or skin.
Bacteriuria without pyuria indicates
bacterial colonisation rather than
infection. Significant bacteriuria is
defined as ≥ 105 organisms/ml of
voided urine (i.e. the number of bacte-
ria that exceed the number usually due
to urethral contamination).The possibil-
ity of contamination is inversely pro-
portional to the reliability of the collec-
tion technique.  Acceptable collection
methods include:
• segmented voided urine specimens
or midstream clean catch
• catheterisation
• suprapubic aspiration. 
Collecting urine specimens
• The clean-catch method is preferred
for routine collection, as it avoids
the risk of infection associated with
invasive methods. With proper col-
lection voided urine usually con-
tains < 104 organisms/ml.  In
asymptomatic patients 104 - 105
organisms/ml represents contami-
nation 95% of the time.  In patients
with symptoms of UTI, a titre of 
≥ 105 organisms/ml carries a 95%
probability of true bacteriuria and
even counts as low as 102 organ-
isms/ml confirm the diagnosis. 
• Catheterisation performed under
scrupulous aseptic technique may
be necessary in those who are
unable to void for neurological or
urological reasons, or those with
an altered sensorium. In non-infect-
ed patients samples obtained in
this manner are less likely to be
contaminated enough to demon-
strate 105 organisms/ml. With
careful technique numbers as low
as 102 organisms/ml are highly
indicative of infection.
• Suprapubic aspiration is particular-
ly useful in adults with paraplegia.
This invasive procedure is unpleas-
ant for the patient but, when per-
formed properly, is not dangerous.
Bladder urine obtained this way is
either sterile or contains significant
growth, even if bacterial numbers
are < 105/ml.
PATHOGENESIS
Urinary tract invasion occurs in differ-
ent ways: 
• Ascending. Most pathogens are
intestinal, and enter the urinary
tract through the urethra into the
bladder. In women vaginal coloni-
sation is an important factor. Once
in the bladder, bacteria may multi-
ply and ascend via the ureters to
the renal pelvis and parenchyma. 
• Haematogenous. This is uncom-
mon in normal individuals, but
blood-borne organisms can infect
the kidneys in patients with staphy-
lococcal bacteraemia from infective
endocarditis or infected oral sites.
Secondary renal infection has also
been described with Candida fun-
gaemia.  
Once colonisation and invasion has
taken place, host-parasite interaction
becomes important in the development
of UTI. Strong host resistance needs to
be overcome by increased bacterial
virulence factors. Conversely, less viru-
lent bacteria are able to infect patients
who are compromised. Normal anti-
bacterial defences of the urinary sys-
tem include high osmolality, low pH
and presence of organic acids in
urine, urine flow and micturition, spe-
cific inhibitors of bacterial adhesion,
the inflammatory response (neu-
trophils, cytokines) and the immune
system. 
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Fig. 1. Classification of UTI.
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A relatively narrow spectrum of
uropathogens cause UTI in patients
with normal urinary tracts. Escherichia
coli is the main organism isolated, fol-
lowed by Staphylococcus saprophyti-
cus. Enterococci and other Gram-nega-
tive enterobacteriaceae such as
Klebsiella, Enterobacter and Proteus
species infrequently cause infection in
this group.6
Acute cystitis and uncomplicated
pyelonephritis are common problems
in women, particularly sexually active
women from 20 - 40 years of age,
and in the postmenopausal popula-
tion. 
In healthy adult men between the ages
of 15 and 50 years, cystitis is very
uncommon and uncomplicated
pyelonephritis hardly ever occurs. 
Uncomplicated cystitis
In women, sexual intercourse,
diaphragm and/or spermicide use,
delayed postcoital micturition and a
history of a recent UTI all increase the
risk of infection. In postmenopausal
women, oestrogen deficiency with
atrophic vaginitis, and less abundant
protective lactobacilli is another con-
tributing factor.1,2,5 Reasons for infec-
tion in men are not always clear, but
risk factors include intercourse with an
infected partner, anal intercourse and
lack of circumcision.2
Cystitis is typically diagnosed clinical-
ly. In women, symptoms include
dysuria with frequency and urgency,
but no fever or constitutional symp-
toms. Suprapubic pain and tenderness
are only found in about 20% of
patients. Major differential diagnoses
are outlined in Table I. 
In men, cystitis presents with irritative
voiding symptoms, but in some
patients may mimic urethritis. Major
differential diagnoses are outlined in
Table II.
In women, uncomplicated cystitis
rarely progresses to symptomatic
upper UTI, and does not have long-
term negative effects with respect to
renal function or mortality. The
causative organisms are predictable,
as are their antimicrobial susceptibility
profiles. This means that women gener-
ally require only an abbreviated
workup and empirical therapy.
Uncomplicated cystitis rarely occurs in
men, so pre-treatment urine culture is
recommended and clinicians should
have a low threshold for urology refer-
ral and investigation.
Table I. Differential diagnosis of uncomplicated cystitis in women
Condition Clinical findings in addition to dysuria and pyuria Common aetiology
Urethritis or Urethral/vaginal discharge containing numerous WBCs Sexually transmitted infections 
vaginitis No suprapubic pain/tenderness, urinary frequency/ (STIs): Chlamydia trachomatis,
urgency and fever Neisseria gonorrhoeae,
Trichomonas vaginalis
Cervicitis Irritative voiding symptoms with mucopurulent vaginal or STIs
cervical discharge (containing numerous WBCs) and 
postcoital bleeding 
Cervical erythema and/or oedema with swabbing-induced 
bleeding
Pelvic As for cervicitis with additional fever, cervical excitation STIs
inflammatory tenderness ± evidence of tubo-ovarian mass E. coli, enteric Gram-negative rods,
disease anaerobes, Streptococcus 
agalactiae and Mycoplasma
and Ureaplasma spp.
Table II. Differential diagnosis of uncomplicated cystitis in men
Condition Clinical findings in addition to dysuria and pyuria Common aetiology
Urethritis Urethral discharge present STIs: C. trachomatis,
No suprapubic pain, urinary frequency/urgency or fever N. gonorrhoeae
Acute prostatitis Back pain, fever, arthralgia/myalgia, rectal pain and E. coli, Proteus spp., 
obstructive voiding symptoms Klebsiella spp.
Tender, boggy prostate on examination
Acute Fever and scrotal swelling + redness STIs or uropathogens (E. coli
epididymitis Epididymal tenderness in patients with recent urinary 
tract instrumentation)
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The reported incidence in
women is 11% per year
and approximately 50% of
all women have at least
one UTI in their lifetime.
Dipstick nitrite is used as a
surrogate marker for bac-
teriuria. Infection due to
uropathogens which do not
reduce nitrate to nitrite
(e.g. Gram-positive cocci)
may be responsible for
false-negative results.
The diagnosis can be presumed if
pyuria is present on leukocyte esterase
dipstick testing or microscopy. The
finding of bacteriuria on microscopy is
more specific but less sensitive.1
In selecting an antibiotic for treatment7-9
several factors should be considered:
• Local microbial resistance patterns
— resistance to β-lactam antibiotics
(amoxicillin or ampicillin) and
trimethoprim-sulfamethoxazole has
become widespread. Using these
drugs as first-line agents will give
low cure rates and is not recom-
mended. 
• Duration of therapy with known
efficacy for the clinical syndrome,
versus cost and adverse effects —
short courses of empirical antibiotic
therapy are highly effective and
cost-efficient in the treatment of
uncomplicated cystitis in women.
Most antimicrobials can be used
for 3 days, with efficacy compara-
ble with longer regimens and fewer
side-effects and lower cost. Single-
dose therapy can be used, but may
result in lower cure rates and more
frequent recurrences. Current guide-
lines for empiric treatment advocate
a 3-day course of oral quinolone or
amoxicillin-clavulanic acid/2nd
generation cephalosporin.
Alternatively, a single dose of
either a quinolone or fosfomycin
can be prescribed. Men who pres-
ent with uncomplicated cystitis
should be treated with a 7-day
course of antibiotics.
• Drug allergy and specific contra-
indications. Quinolone should not




In women, this infection is similar to
cystitis and is caused by similar bacte-
ria. The clinical spectrum ranges from
a cystitis-like illness with mild flank
pain and fever or rigors, to a more
severe syndrome of urosepsis or Gram-
negative septicaemia.1,2,5
Urine microscopy establishes the pre-
sumptive diagnosis. Pyuria is present
and WBC casts may be seen. Pre-
treatment urine culture and sensitivity
tests should be obtained in all patients
with suspected pyelonephritis, and
blood culture should be taken in hospi-
talised patients (15 - 20% are posi-
tive).
Clinical severity will dictate treatment
and further investigations:8-10
• Patients with mild illness can safely
receive oral treatment as outpa-
tients with a quinolone or amoxi-
cillin-clavulanic acid or 2nd gener-
ation cephalosporin for 10 - 14
days. 
• Those with moderate-to-severe ill-
ness or patients with nausea or
vomiting should be hospitalised for
initial parenteral treatment with
quinolone or ceftriaxone or amino-
glycoside ± ampicillin. With
improvement or resolution of the
clinical picture after 48 - 72 hours,
the remaining treatment can be
given orally. Fever and flank pain
persisting beyond 72 hours of ther-
apy warrant further investigation:
urine cultures should be repeated
and the urinary tract imaged (ultra-
sonography or computed tomogra-
phy) to exclude abscess formation,
obstruction or unrecognised urologi-
cal abnormalities. Antibiotics
should be changed according to
susceptibility profiles of isolated
bacteria.
• Post-treatment urine culture is
preferable.
Recurrent cystitis in women
About 20% of young women with nor-
mal urinary tracts have recurrent UTI
within 6 months of an initial episode
of cystitis.2 Over 90% of recurrences
are due to reinfection — this occurs
after 2 weeks of completing antibiotic
treatment and may be caused by the
same or a different organism.
Occasionally the original uropathogen
persists and causes recurrence within
2 weeks — this defines a relapse
infection. 
In addition to behaviour, host genetic
factors and bacterial factors contribute
to recurrence.
Prophylaxis1,2,7 is indicated for women
who experience at least 2 sympto-
matic UTIs in less than 6 months.
Eradication of active infection should
be confirmed by negative culture at
least 1 - 2 weeks after discontinuation
of initial treatment. The choice of pro-
phylactic regimen should be based on
susceptibility of bacteria isolated from
prior UTI, drug allergies and intoler-
ance.
Effective measures decrease recur-
rences by up to 95% and may prevent
pyelonephritis. These measures
include:
• Continuous prophylaxis — an
antibiotic is taken daily for at least
6 months. It has been safely and
effectively continued for longer
without emergence of microbial
resistance. 
• Postcoital prophylaxis — in women
who describe a clear relation
between intercourse and UTI, a sin-
gle dose of an antimicrobial is
taken with each act of coitus. 
Another convenient, safe and inexpen-
sive strategy is intermittent patient-initi-
ated treatment.1
• Women are instructed to start a 3-
day course of an antibiotic agent
at symptom onset. They are
advised to seek medical attention if
there is no resolution by 48 - 72
hours after completion of treatment.
Additional corrective measures: 
• Atrophic vaginitis should be treated
with topical oestrogen cream in
postmenopausal women.
• Women exposed to spermicides
from diaphragms or condoms
should consider alternative methods
of contraception.
• There is no evidence that recurrent
cystitis can be prevented by post-
coital voiding. Poor urinary
hygiene does not predispose to
recurrent UTI and there is no ration-
ale in giving specific instructions
regarding voiding, wiping patterns,
douching or wearing of pantyhose.1
Cranberry juice7 has been long advo-
cated as a measure to reduce the
recurrence rate. Constituent glycopro-
teins and proanthocyanidins appear to
inhibit bacterial adherence to uro-
epithelium. Randomised trials suggest-
ed a daily dose of 200 - 750 ml juice
to reduce recurrence by 12 - 20%.
Variable therapeutic effect can be
ascribed to variations in actual cran-
berry content of juice, capsules or
tablets.
Probiotic formulations7,11 containing
various lactobacilli and bifidobacteria
can also be used as adjunctive treat-
ment. The primary aim of vaginal
application of probiotic-containing
capsules is to restore the protective
microflora. Various studies have shown
that UTI recurrence can be significant-
ly reduced by using probiotic capsules
weekly for 1 year with similar efficacy
to continuous antibiotic prophylaxis
and without side-effects.
Complicated UTI
Where there are underlying medical
conditions, pregnancy, hospitalisation
or long-term urinary catheter use, UTI
(whether cystitis or pyelonephritis)
should be considered complicated.
The frequency and impact of compli-
cated UTI are determined by the
underlying abnormalities and compli-
cating factors may not be immediately
obvious.2,5
The clinical spectrum ranges from mild
cystitis to life-threatening urosepsis.
Prolonged periods of asymptomatic
bacteriuria often occur. A common
feature is an inability to effectively
clear organisms from the urinary tract
(obstruction) or an increased frequen-
cy of introduction of bacteria into the
urinary tract (instrumentation or reflux).
A high frequency of recurrent infection
is anticipated. If correction is possible,
further infection may be prevented. 
Complications of
pyelonephritis2,12
• Emphysematous pyelonephritis (EP)
is an acute necrotising renal
parenchymal infection with
intrarenal ± perinephric gas forma-
tion, primarily seen in diabetics.
Delayed diagnosis adds to high
morbidity and mortality.               
• Intrarenal abscesses are most com-
monly due to Staphylococcus
aureus infection with 30 - 50% of
patients having concomitant dia-
betes mellitus.
• Acute papillary necrosis is pre-
sumed to be due to marginal blood
supply which is further stressed by
infection leading to infarction and
papillary sloughing. Diagnosis is
confirmed on retrograde urogra-
phy.
Complicated UTI has a more diverse
aetiology.5,6 Hosts with underlying dis-
ease are susceptible to infection with
antimicrobial-resistant and/or unusual
organisms and are at a higher risk for
treatment failure.
E. coli remains the commonest infect-
ing organism, but is isolated from only
about 50% of patients. The remainder
of isolates includes other enterobacteri-
aceae (Klebsiella spp., Proteus spp.),
Pseudomonas spp. and Gram-positives
(enterococci, coagulase-negative
staphylococci and group B streptococ-
ci). 
Pre-treatment culture (urine ± blood) is
mandatory in all patients. Urine cul-
ture should be repeated 1 - 2 weeks
after completion of therapy, as the
recurrence rate is high (especially if
the underlying abnormality persists).
Treatment must be tailored to individ-
ual patient circumstances. Previous
bacteriological test results, severity of
illness and allergy history need to be
considered.
• Oral fluoroquinolones provide a
broad spectrum of antimicrobial
activity and should be given for at
least 7 days to patients with mild-
to-moderate illness who can be
treated as outpatients.
• More seriously ill patients should
be hospitalised and empirical par-
enteral broad-spectrum antibiotics
given. Preferred antimicrobials are
quinolones or ceftriaxone or amino-
glycoside ± ampicillin or
piperacillin-tazobactam (suspected
enterococcal UTI). Therapy should
be modified when the infecting
organism has been identified and
susceptibilities are known.
Treatment duration is usually 10 -
14 days, but Pseudomonas and
enterococcal infections may war-
rant more prolonged therapy. 
UTI in patients with
diabetes mellitus5,6,12-14
In diabetic women there is a 2 - 4-fold
higher incidence of bacteriuria.
Contributing host factors include poor
glycaemic control with impaired leuko-
cyte function, recurrent vaginitis,
anatomical and functional abnormali-
ties and microangiopathy. Most cases
(80%) are due to ascending infection
with abovementioned uropathogens
and non-albicans Candida spp.
Haematogenous spread of infection
(mostly S. aureus) accounts for the
remainder of cases.
Upper tract involvement occurs in up
to 80% of diabetics with UTI, and
complications (emphysematous
pyelonephritis, abscess formation or
papillary necrosis) also occur more
frequently. Clinical presentation is simi-
lar to that in non-diabetic patients
except that bilateral infection is more
common. Occasionally it may be
asymptomatic, particularly in individu-
als with metabolic disturbance or
reduced level of consciousness.
Haematuria or flank pain may be 
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Fungal UTI is frequently
seen in diabetics and the
extent ranges from lower
tract colonisation to clini-
cal cystitis, pyelonephritis
and abscess formation, and
fungaemia. 
noted in patients with papillary necro-
sis and occasionally pneumaturia may
be seen.
Fungal UTI is frequently seen in diabet-
ics and the extent ranges from lower
tract colonisation to clinical cystitis,
pyelonephritis and abscess formation,
and fungaemia. 
Investigation of possible UTI in diabet-
ic patients should include urinalysis
and culture prior to initiation of thera-
py, together with assessment of renal
function and glycaemic status. In
patients with presumed pyelonephritis,
a blood culture should be routine. 
Imaging is essential owing to the high
incidence of complications. All
patients should have an abdominal 
X-ray to exclude renal emphysema.
Severely ill patients should have
screening ultrasound or computed
tomography to exclude obstruction
and identify calculi and inflamed
oedematous parenchyma. Contrast
enables a more accurate recognition
of inflamed renal tissue, air or pus col-
lection, but its use may be complicat-
ed by transient or permanent loss of
renal function.
Treatment for bacterial UTI includes
hydration, glycaemic control and non-
nephrotoxic parenteral antibiotics. 
Fungal UTI should be treated with
removal of catheters if present and
amphotericin B bladder irrigation.
Alternatively a single intravenous dose
of amphotericin B or oral fluconazole




and prompt surgical or percutaneous
drainage is required for intrarenal or
perinephric abscesses.
UTI in pregnancy5,7,15
UTI is one of the most common infec-
tions of pregnancy. Bacteriuria occurs
in 5 - 9% of women — a significant
number of whom will develop sympto-
matic UTI during the course of the
pregnancy. Most infections are caused
by E. coli and causative host factors
are physiological changes (smooth-
muscle relaxation with stasis, less
robust humoral immune response) and
mechanical factors (pressure on blad-
der with reflux).
The clinical entities include asympto-
matic bacteriuria (ASB), cystitis and
pyelonephritis. Patients with untreated
or inadequately treated ASB are at
high risk of developing pyelonephritis
which can lead to preterm labour, pre-
maturity and low-birth-weight infants.
A urine culture should be obtained
from all women in early pregnancy.
Therapeutic options for treatment of
UTI are guided by pathogen suscepti-
bility and antibiotic safety profile in
pregnancy (beta-lactams, nitrofuran-
toin).
• ASB should be treated with a 3-
day course of antimicrobials.
• Symptomatic UTI should be treated
for 7 days.
• Once UTI is documented, monthly
screening urine cultures should be
obtained for the duration of the
pregnancy.
• Recurrent or persistent UTI may
warrant daily antimicrobial prophy-
laxis and urological evaluation.
UTI in geriatric and
institutionalised or
catheterised patients2-6
Predisposing factors for development
of UTI in the elderly patient include
altered elimination (faecal impaction,
urinary retention, and anticholinergic
drugs), anatomical variations (genital
prolapse or prostate hypertrophy),
hygiene issues (faecal soiling), neuro-
logical impairment affecting mobility,
and voiding and hormonal changes.
The frail elderly with multiple health
problems and complicated UTI often
have an atypical or subtle presentation
(delirium, agitation, incontinence or
increased urine loss). Diagnosis is
often delayed. Treatment should be
according to principles as outlined for
complicated UTI and complicating or
contributing factors should be
addressed. The best prophylaxis is to
minimise catheter use and to improve
general hygiene.
In hospital or long-term care,
indwelling catheters are the major
cause of UTIs. Additional risk factors
include increasing duration of
catheterisation, no administration of
systemic antibiotics, female gender
and older age, rapidly fatal underly-
ing disease, diabetes mellitus and azo-
taemia as well as faulty aseptic man-
agement of catheter and/or collecting
system. 
Catheter-related bacteriuria is defined
as the presence of ≥ 103 CFU/ml of a
predominant bacterial species and is
usually asymptomatic, uncomplicated
and resolves after catheter removal. It
is however associated with increased
morbidity and mortality.
The following should be kept in mind
with regard to catheterisation:
• Avoid using catheters whenever
possible.
• Appropriate indications for catheter
use: bladder outlet obstruction,
incontinence (with open sacral or
perineal wounds; on request at end
of life), output monitoring in critical-
ly ill patients, and during pro-
longed surgical procedures. 
• A closed catheter drainage system
should be used and proper aseptic
techniques during insertion and
maintenance must be adhered to.
• There is little evidence to suggest
benefit with bladder irrigation,
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antimicrobial drugs in drainage
bags or rigorous meatal cleaning.
Prophylactic systemic antibiotics
are most useful in patients requiring
catheterisation for 3 - 14 days and
the benefit of systemic antibiotic
prophylaxis is proven in patients
undergoing surgery and requiring
indwelling catheterisation (renal
transplantation or transurethral
resection of the prostate).
• More research is needed to evalu-




ASB2,5 is the presence of ≥ 105 organ-
isms/ml of urine on at least 2 succes-
sive cultures in patients without UTI
symptoms. Incidence increases with
age (Table III).
There appears to be a higher frequen-
cy of infection with coagulase-negative
staphylococci and Enterococcus spp. 
In healthy non-pregnant women, men
and the well elderly ASB poses no
threat, as symptomatic infection with
complications rarely develops.
Screening is useful only where treat-
ment is mandatory, as in the following
situations:2,5,9
• individuals with ASB undergoing
urological procedures are at risk of
invasive infection (including bacter-
aemia and sepsis)
• patients with renal allografts in the
early post-transplant period
• ASB in pregnant women, if left
untreated, may progress to sympto-
matic infection (especially
pyelonephritis) which is 4-fold high-
er than in non-pregnant women. 
References available on request.
Table III. Incidence of asymptomatic bacteriuria in different
patient groups
Patient group Incidence
Non-pregnant and pregnant women 5 - 9%
Community-dwelling elders (≥ 65 years)
• Women 20 - 25% 
• Men 5 - 10% 
Patients in long-term-care facilities
• Without catheters ± 40%
• With catheters Nearly 100%
UTI is a commonly encountered prob-
lem in clinical practice, particularly
in women.
Symptomatic UTI includes lower or
upper tract involvement (cystitis or
pyelonephritis). 
UTIs that occur in the setting of
underlying medical conditions, preg-
nancy or long-term use of a catheter
are considered to be complicated.
The incidence of asymptomatic bac-
teriuria increases with age. However,
it poses no threat in healthy non-
pregnant women, men and the well
elderly. Screening should be limited
to selected patient groups where
treatment is mandatory (pregnancy,
prior to urinary tract instrumentation,
and renal transplantation).
UTI in the diabetic, elderly or debili-
tated patient may lack classic presen-
tation.
Complications of upper tract infection
are emphysematous pyelonephritis,
abscess formation, papillary necrosis
and bacteraemia. These are particu-
larly prevalent in patients with dia-
betes mellitus.
Pregnant women with UTI are at risk
of preterm labour, prematurity and
low-birth-weight infants — they
should undergo urine screening early
in pregnancy and asymptomatic bac-
teriuria should be treated aggressive-
ly.
Investigation and treatment of UTI
should be individualised according
to the clinical setting in which it
occurs. 
Dipstick tests are cheap, fast and
convenient screening tools in patients
with uncomplicated cystitis. Urine cul-
tures should be performed in patients
with complicating factors and blood
cultures may be positive in up to
20% of patients with upper tract
involvement.
Factors that should be taken into con-
sideration in selecting an antibiotic
for treatment are: local microbial sus-
ceptibility patterns, duration of thera-
py with known efficacy for the clini-
cal syndrome versus cost and
adverse effects and patient factors
(allergy and specific contraindica-
tions) as well as clinical severity.
Antibiotic prophylaxis is indicated for
women who experience at least 2
symptomatic UTIs in less than 6
months. Alternative strategies are
intermittent patient-initiated treatment,
correction of biological or behaviour-
al factors and use of probiotics and
cranberry extracts. 
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